Samsung Biologics stock
Price history
−24.20% over the period1 year: from ₩1,877,331.38 (November 17, 2025) to ₩1,423,000.00 (November 16, 2026), −24.20%.
Show chart data
Closing prices adjusted for splits: the last close of each month.
| Date | Close |
|---|---|
| November 16, 2026 | ₩1,423,000.00 |
| October 30, 2026 | ₩1,487,000.00 |
| September 30, 2026 | ₩1,381,619.88 |
| August 31, 2026 | ₩1,518,000.00 |
| July 31, 2026 | ₩1,485,000.00 |
| June 30, 2026 | ₩1,391,000.00 |
| May 29, 2026 | ₩1,363,000.00 |
| April 30, 2026 | ₩1,470,000.00 |
| March 31, 2026 | ₩1,504,000.00 |
| February 27, 2026 | ₩1,778,000.00 |
| January 30, 2026 | ₩1,745,000.00 |
| December 30, 2025 | ₩1,695,000.00 |
| November 28, 2025 | ₩1,607,000.00 |
| November 17, 2025 | ₩1,877,331.38 |
At a glance
The company
Manufactures biopharmaceuticals and offers contract development and manufacturing services including antibody-drug conjugates and mRNA products
Latest results
Quarter to September 30, 2026 · EPS ₩8,448.73 (estimate ₩9,841.69)
Next event
TickerLandia's take on Samsung Biologics
- Cheaper than usual relative to earnings: P/E on the latest fiscal year 38 vs a median of 92 over its last 8 fiscal years.
- Cheaper than similar companies: trailing 12-month P/E 33 vs 40 (−17%) in a group of 8.
- Strong point: Earnings stability (85/100 in its group). Weak point: Market momentum (29/100).
- “Below historical valuation” (South Korea): No. 3 of 7.
Analysis calculated by TickerLandia from financial statements and prices, with public rules. Not investment advice. How we analyse stocks
Where the price stands
−28.38% from the 52-week high
Analysts · 27 analysts
Average target₩1,879,148.10+32.06% vs. price
Buy 25 · Hold 2 · Sell 0 · Buy
TickerLandia Fingerprint: Samsung Biologics
Compared with similar companies: very high earnings stability.
Financials and price compared with 61 companies in the biotechnology industry, worldwide. Momentum and risk compared with 1,069 Asia-Pacific stocks.
Priceaverage54
How much it costs relative to what it produces.
Metric Value Position in group P/E (trailing 12 months) 33.4 40 Price/book 8.11 65 EV/EBITDA 22.7 49 Forward P/E 30.4 57 Price/sales 12.8 61 Profitabilityhigh69
How much it earns on revenue and capital.
Metric Value Position in group Operating margin 45.5% 88 Net margin 38.7% 86 ROE 18.5% 65 Gross margin 54.2% 30 ROA 9.6% 76 Earnings stabilityvery high85
How steady its margins were over the last five annual reports.
Metric Value Position in group Margin variabilitycounts in reverse: lower means more earnings stability 5.9% 87 Loss-making yearscounts in reverse: lower means more earnings stability 0 of 5 annual reports 84 Growthaverage56
How fast revenue and earnings are growing.
Metric Value Position in group Average revenue growth (3 years) +14.94% 39 Revenue growth (year over year) +30.20% 63 Earnings growth (year over year) +32.90% 65 Financial strengthaverage42
How well it would weather a hard period: debt, liquidity, interest.
Metric Value Position in group Net debt/EBITDAcounts in reverse: lower means more financial strength 0.29 30 Interest coverage 70.9 75 Current ratio 1.80 16 Debt/equitycounts in reverse: lower means more financial strength 0.15 46 Market momentumweak29
How the stock has moved compared with the market.
Metric Value Position in group 1-year return −24.84% 14 Distance from 200-day average −5.63% 43 Riskhigh65
How much the price swings.
Metric Value Position in group Volatility (60 days) 48.5% 69 Maximum drawdown (12 months) 39.8% 61
1 dimension without enough data. Position in the group from 0 to 100 (100 = highest value): it describes, it does not rate. Tap a row for the metrics. Calculated on November 16, 2026. An indicator calculated by TickerLandia from financial statements and market data. How it is calculated
Valuation
Samsung Biologics is cheaper than in the past and cheaper than similar companies
On the latest fiscal year's earnings (2025), Samsung Biologics's P/E today is 38.4, below the median of its last 8 fiscal years (92.4; between 45.8 and 224.4 from 2018 to 2025). Samsung Biologics's P/E (trailing 12 months): 33.4, −17% against the median of a group of 8 similar companies (40.2).
Compared with 8 similar companies
| Metric | Samsung Biologics | Position in the group | Band |
|---|---|---|---|
| P/E (trailing 12 months) | 33.4 | Low | |
| Forward P/E | 30.4 | Middle | |
| Operating margin | 45.5% | High | |
| ROE | 18.5% | High | |
| Debt/equity | 0.15 | Middle |
P/E at fiscal year end; today on the latest fiscal year's earnings. Grey band: the middle half of the group; tick: the median; dot: Samsung Biologics. All multiples and dividends
TickerLandia analysisHow it is calculated
The financials
The business in numbers
Revenue
₩1.32T
Latest quarter · Q2 2026
Net income
₩430.65B
Latest quarter · Q2 2026
Quarterly net margin
32.6%
Latest quarter · Q2 2026
Numbers and valuation
Full valuation- Market cap
- ₩65.69T
- P/E
- 33.4
- EPS
- ₩45,556.40
- Volume
- 54.88K
- Daily trading
- €69.99M
How Samsung Biologics is changing
All resultsRevenue grew 31.4% a year on average over the last 5 years
Operating margin rose from 32.8% to 45.4%
Less cash than profit: free cash flow equal to 51% of net income
Returns
Samsung Biologics returns with dividends
₩1,000 invested in Samsung Biologics 5 years ago, on November 16, 2021, would be worth ₩1,073 today: +7.26% in total, +1.41% per year. This is the price return only: dividends are excluded.
| Period | Samsung Biologics | ₩1,000 becomes |
|---|---|---|
| 1 month | +9.63% | ₩1,096 |
| 6 months | +0.28% | ₩1,003 |
| Year to date | −16.05% | ₩840 |
| 1 year | −24.20% | ₩758 |
| 3 years | +26.44% | ₩1,264 |
| 5 years | +7.26% | ₩1,073 |
| 10 years | +450.19% | ₩5,502 |
From 1 year up with dividends reinvested, before taxes; under a year price only. Calculate your investment
The chart in detail
Samsung Biologics: technical analysis
Samsung Biologics shows no clear trend: the price and its 50- and 200-session averages are not aligned. The price is 27.6% below its all-time closing high (₩1,965,000.00, January 15, 2026).
- Trend
- No clear trend
- RSI (14 sessions)
- 50
- Between 30 and 70
- vs 200-session average
- −4.67%
Support and resistance
Price areas where Samsung Biologics has stopped several times in the last year. They describe the chart; they are not forecasts.
- Resistance₩1,638,000.00+15.11%5 touches, last on August 20, 2026
- Resistance₩1,578,500.00+10.93%4 touches, last on November 6, 2026
- Resistance₩1,478,666.67+3.91%6 touches, last on October 26, 2026
- Last price₩1,423,000.00
- Support₩1,422,570.69−0.03%4 touches, last on October 1, 2026
- Support₩1,360,333.33−4.40%3 touches, last on October 30, 2026
- Support₩1,302,000.00−8.50%2 touches, last on July 9, 2026
Volatility and risk
- Volatility (60 sessions, annualised)
- 48.5%
- Largest fall in the last year
- −39.85%
Close of November 16, 2026. Descriptive data calculated on daily prices: it describes the chart and is not investment advice. Beta and volatility describe the last year and can change a lot from one year to the next. How we calculate it
Samsung Biologics: seasonality
Average monthly price change over 10 years
Over the last 10 years, the strongest month for Samsung Biologics has been October: +5.99% on average, positive in 7 years out of 10. The weakest has been November: −2.46% on average, positive in 4 years out of 9.
Show chart data
| Month | Average | Median | Positive years |
|---|---|---|---|
| January | +4.19% | +4.93% | 7 of 10 |
| February | −1.20% | −0.38% | 5 of 10 |
| March | −0.45% | +2.97% | 6 of 10 |
| April | +3.17% | +1.24% | 7 of 10 |
| May | +0.10% | −0.76% | 5 of 10 |
| June | +4.53% | −0.44% | 4 of 10 |
| July | +2.63% | +4.39% | 6 of 10 |
| August | +3.21% | +3.13% | 6 of 10 |
| September | +0.75% | −1.88% | 3 of 10 |
| October | +5.99% | +5.87% | 7 of 10 |
| November | −2.46% | −1.25% | 4 of 9 |
| December | +3.88% | +4.96% | 7 of 10 |
Price change only, dividends excluded. Past seasonality does not predict future moves.
The company
Samsung Biologics and its competitors
The business centres on manufacturing biopharmaceutical products, which it also commercializes, distributes and sells. Its development work runs from cell line development and process development to analytical development and non-GMP and CGMP manufacturing. Downstream, it operates aseptic filling, freeze-drying, packaging and cold-chain logistics, alongside quality services such as stability studies, environmental monitoring and biosafety testing. Its portfolio also includes antibody-drug conjugates and mRNA products, and its customers and sales reach South Korea, Europe, the United States and other international markets.
- Headquarters
- Incheon, South Korea
- Employees
- 5,326
- Founded
- 2011
- Chief executive
- John Chongbo Rim
| Company | Market cap | Operating margin | P/E (trailing 12 months) | 6 months |
|---|---|---|---|---|
| Samsung Biologics207940 | $49.13B | 45.5% | 33.4 | +0.28% |
| CSLCSL | $65.65B | 26.8% | — | +106.74% |
| Celltrion068270 | $36.68B | 31.6% | 26.4 | +19.29% |
| WuXi Biologics (Cayman)2269 | $24.52B | 32.4% | 35.1 | +38.78% |
| Innovent Biologics1801 | $18.84B | 7.4% | 111.5 | +2.32% |
| Sichuan Kelun-Biotech Biopharmaceutical6990 | $13.65B | -0.2% | — | +0.78% |
Same industry or related industries, similar size. Compare Samsung Biologics with its competitors · Full profile
